國立高雄大學圖資館 |

Language: English

Back

Nanomedicines for the prevention and treatment of infectious diseases

Record Type:	Electronic resources : Monograph/item
Title/Author:	Nanomedicines for the prevention and treatment of infectious diseasesedited by Vandana B. Patravale, Abhijit A. Date, Anil B. Jindal.
other author:	Patravale, Vandana B.
Published:	Cham :Springer International Publishing :2023.
Description:	xvi, 404 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	Communicable diseasesPrevention.
Online resource:	https://doi.org/10.1007/978-3-031-39020-3
ISBN:	9783031390203$q(electronic bk.)

Nanomedicines for the prevention and treatment of infectious diseases
Nanomedicines for the prevention and treatment of infectious diseases[electronic resource] /edited by Vandana B. Patravale, Abhijit A. Date, Anil B. Jindal. - Cham :Springer International Publishing :2023. - xvi, 404 p. :ill., digital ;24 cm. - AAPS advances in the pharmaceutical sciences series,v. 562210-738X ;. - AAPS advances in the pharmaceutical sciences series ;3..

Nanocarriers for delivery of peptide antibiotics -- NANOMEDICINES FOR THE PULMONARY DELIVERY OF ANTIBIOTICS -- Inhalable nanomedicines for the treatment of pulmonary aspergillosis -- Nanomedicines for the treatment of systemic candidiasis -- Nanomedicine for the treatment of vaginal candidiasis -- Nanomedicines for the treatment of veterinary parasitic infections -- Role of Nanotechnology Against Malaria: Current Perspectives and Strategies -- NANOMEDICINES FOR THE TREATMENT OF TRYPANOSOMIASIS -- Nanomedicines to improve oral delivery of antiretroviral drugs -- Nano-Adjuvants -- Nanoscale Vaccines for Influenza -- Nano-scale vaccines for the prevention of hepatitis B virus infection -- Nanoscale Vaccines for the Prevention of COVID-19.

The COVID-19 pandemic has altered the world and reiterated the perpetual need for the development of effective strategies for the prevention and treatment of infectious diseases. While globally prevalent infectious diseases receive extensive attention in terms of drug development and delivery, the neglected and/or emerging infectious diseases that affect developing countries are often overlooked. From the commercialization of AmBisome® to the emergency authorization of mRNA-based vaccines, nanotechnology has played a vital role in the prevention and treatment of infectious diseases. More importantly, nanotechnology has enabled the effective utilization of existing armamentarium against infectious diseases leading to improved therapeutic outcomes with a concomitant reduction in the side effects associated with anti-infective agents. In particular, nanotechnology can bring about a paradigm shift in the management of neglected and emerging infectious diseases and may compensate for the lack of drug discovery efforts. This book addresses an unmet need in pharmaceutical and medical education. This book provides a comprehensive and up-to-date overview of the latest advancements in nanomedicine, which show great potential for preventing and treating infectious diseases. Covering a wide range of topics, it explores various formulation strategies for combating microbial, fungal, parasitic, and viral infections. The book emphasizes the advantages of nano-scale vaccines over traditional ones and discusses their production. It also examines feasible treatment approaches for diseases like malaria, trypanosomiasis, candidiasis, Hepatitis B, HIV, and the ongoing COVID-19 pandemic. Additionally, it highlights the role of nano-adjuvants in vaccine development, as well as the use of peptide antibiotics and pulmonary delivery of drugs, which open up new possibilities in fighting infectious diseases. Furthermore, the book explores the critical role of nanomedicine in addressing veterinary parasitic infections. The emergence of nanotechnology has led to novel strategies for diagnosing, treating, and preventing parasitic infections in animals.

ISBN: 9783031390203$q(electronic bk.)

Standard No.: 10.1007/978-3-031-39020-3doiSubjects--Topical Terms:

372465
Communicable diseases
--Prevention.

LC Class. No.: RC112

Dewey Class. No.: 616.9

Nanomedicines for the prevention and treatment of infectious diseases
LDR:04024nmm a2200337 a 4500 001 651786
003 DE-He213
005 20231031133957.0
006 m d
007 cr nn 008maaau
008 240327s2023 sz s 0 eng d
020 $a 9783031390203$q(electronic bk.)
020 $a 9783031390197$q(paper)
024 7 $a 10.1007/978-3-031-39020-3 $2 doi
035 $a 978-3-031-39020-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC112
072 7 $a PSB $2 bicssc
072 7 $a MED072000 $2 bisacsh
072 7 $a PNB $2 thema
082 0 4 $a 616.9 $2 23
090 $a RC112 $b .N186 2023
245 0 0 $a Nanomedicines for the prevention and treatment of infectious diseases $h [electronic resource] / $c edited by Vandana B. Patravale, Abhijit A. Date, Anil B. Jindal.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a xvi, 404 p. : $b ill., digital ; $c 24 cm.
490 1 $a AAPS advances in the pharmaceutical sciences series, $x 2210-738X ; $v v. 56
505 0 $a Nanocarriers for delivery of peptide antibiotics -- NANOMEDICINES FOR THE PULMONARY DELIVERY OF ANTIBIOTICS -- Inhalable nanomedicines for the treatment of pulmonary aspergillosis -- Nanomedicines for the treatment of systemic candidiasis -- Nanomedicine for the treatment of vaginal candidiasis -- Nanomedicines for the treatment of veterinary parasitic infections -- Role of Nanotechnology Against Malaria: Current Perspectives and Strategies -- NANOMEDICINES FOR THE TREATMENT OF TRYPANOSOMIASIS -- Nanomedicines to improve oral delivery of antiretroviral drugs -- Nano-Adjuvants -- Nanoscale Vaccines for Influenza -- Nano-scale vaccines for the prevention of hepatitis B virus infection -- Nanoscale Vaccines for the Prevention of COVID-19.
520 $a The COVID-19 pandemic has altered the world and reiterated the perpetual need for the development of effective strategies for the prevention and treatment of infectious diseases. While globally prevalent infectious diseases receive extensive attention in terms of drug development and delivery, the neglected and/or emerging infectious diseases that affect developing countries are often overlooked. From the commercialization of AmBisome® to the emergency authorization of mRNA-based vaccines, nanotechnology has played a vital role in the prevention and treatment of infectious diseases. More importantly, nanotechnology has enabled the effective utilization of existing armamentarium against infectious diseases leading to improved therapeutic outcomes with a concomitant reduction in the side effects associated with anti-infective agents. In particular, nanotechnology can bring about a paradigm shift in the management of neglected and emerging infectious diseases and may compensate for the lack of drug discovery efforts. This book addresses an unmet need in pharmaceutical and medical education. This book provides a comprehensive and up-to-date overview of the latest advancements in nanomedicine, which show great potential for preventing and treating infectious diseases. Covering a wide range of topics, it explores various formulation strategies for combating microbial, fungal, parasitic, and viral infections. The book emphasizes the advantages of nano-scale vaccines over traditional ones and discusses their production. It also examines feasible treatment approaches for diseases like malaria, trypanosomiasis, candidiasis, Hepatitis B, HIV, and the ongoing COVID-19 pandemic. Additionally, it highlights the role of nano-adjuvants in vaccine development, as well as the use of peptide antibiotics and pulmonary delivery of drugs, which open up new possibilities in fighting infectious diseases. Furthermore, the book explores the critical role of nanomedicine in addressing veterinary parasitic infections. The emergence of nanotechnology has led to novel strategies for diagnosing, treating, and preventing parasitic infections in animals.
650 0 $a Communicable diseases $x Prevention. $3 372465
650 0 $a Communicable diseases $x Treatment. $3 754960
650 0 $a Nanomedicine. $3 273406
650 1 4 $a Pharmaceutics. $3 913065
650 2 4 $a Nanomedicine and Nanotoxicology. $3 911848
650 2 4 $a Diseases. $3 276053
650 2 4 $a Nanobiotechnology. $3 679667
650 2 4 $a Pharmacology. $3 218135
700 1 $a Patravale, Vandana B. $3 962157
700 1 $a Date, Abhijit A. $3 962158
700 1 $a Jindal, Anil B. $3 957847
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a AAPS advances in the pharmaceutical sciences series ; $v 3. $3 559046
856 4 0 $u https://doi.org/10.1007/978-3-031-39020-3
950 $a Biomedical and Life Sciences (SpringerNature-11642)